Author's posts
Importing Drugs From Canada Not Viable For Lowering U.S. Prices
Americans are rightly concerned about the price of prescription medicines. New ideas and approaches are needed to deal with this issue.
Rare Disease R&D Investments Likely To Grow In Biopharma
Given these advantages, it is hard to believe that rare diseases won’t take up a bigger proportion of biopharma R&D dollars in the future.
The Biopharmaceutical Cartel And High Drug Prices
But rather than use tired attacks on the biopharmaceutical industry, upon which we depend to bring much needed treatments and cures, let’s focus the discusion on solutions that can help people pay for medicine while providing the type of revenues neede…
Outcomes-based Pricing Not A Panacea For High Priced Drugs
If the drug doesn’t work, you get your money back. Such a mantra can only improve the industry’s reputation.
How Will The Failure Of Biogen’s Alzheimer’s Drug, Aducanumab, Impact R&D?
The death of an important drug like aducanumab will have both a short and a long term effect on Biogen as a company and especially on R&D.
How Will The Failure Of Biogen’s Alzheimer’s Drug, Aducanumab, Impact R&D?
The death of an important drug like aducanumab will have both a short and a long term effect on Biogen as a company and especially on R&D.
The Absurdity Of Avoiding Vaccines
My brother and I had been sick for a while and we didn’t seem to be getting any better.
The Challenges In Bringing An Anti-Aging Pill To Market
But an anti-aging pill available for the masses is not around the corner. It might not even appear in our lifetime.
Does The NIH Deserve A Piece Of Biopharma’s Profits?
Decades ago, the U.S. believed that investments in research were important for the public good – for our defense, for our health and for our economic prosperity.
Based On Sales Forecasts For 2018 FDA Approved Drugs, Big Pharma Not Just Focused On Blockbusters
What is driving these companies to develop drugs with poorer sales prospects than were previously deemed essential?
